141 Years of Discovery

John Berry Haycraft (University of Edinburgh)

Haycraft observed that blood drawn in the presence of leech anterior-sucker extract failed to coagulate, demonstrating that Hirudo medicinalis produces a specific anticoagulant substance. Published in Proc. R. Soc. Lond. 36: 478-487. The first demonstration that any organism produces a selective anticoagulant, launching 141 years of leech pharmacology research.

Carl Jacobj and his Göttingen co-workers (Franz 1903, Bodong 1905)

Coined the term 'hirudin' for Haycraft's anticoagulant principle, establishing the nomenclature still used 120+ years later.

Various European clinicians

Initial clinical trials of crude leech extract for treatment of thrombosis. Limited by impurity, anaphylaxis risk, and lack of standardization — but established the therapeutic concept of injectable leech-derived anticoagulant 95 years before lepirudin's FDA approval.

William Henry Howell + Jay McLean (Johns Hopkins)

Discovery of heparin established a competing anticoagulant paradigm. The Howell/McLean discovery overshadowed leech pharmacology for decades, but the structural and mechanistic differences (heparin requires antithrombin cofactor; hirudin directly inhibits thrombin) ultimately defined two distinct anticoagulant classes both still used today.

Fritz Markwardt (University of Greifswald)

Definitive characterization of hirudin as a 65-amino-acid peptide that forms a 1:1 stoichiometric complex with thrombin. Markwardt established the three foundational facts: hirudin is a protein (not small molecule), it binds thrombin stoichiometrically (not catalytically), and its mechanism is fundamentally distinct from heparin's antithrombin-mediated action. Published in Naturwissenschaften 44: 653-656 — the most-cited paper in the leech-pharmacology canon.

Dieter Bagdy + colleagues

Complete amino acid sequencing of hirudin (65 residues, 3 disulfide bonds, sulfated Tyr63). Enabled subsequent recombinant expression and pharmaceutical development by establishing the molecular blueprint.

Multiple groups (Plough/Schering-Plough, Hoechst/Behringwerke)

First recombinant expression of hirudin in E. coli and yeast systems. Removed dependence on leech-extracted hirudin, enabled pharmaceutical-scale production, and unblocked the path to clinical drug development.

Tuszynski (antistasin from Haementeria officinalis), Seymour et al. (decorsin)

Discovery of antistasin (factor Xa inhibitor) and decorsin (RGD-containing antiplatelet) expanded the leech-derived drug-class concept beyond hirudin. Antistasin was among the early natural factor Xa inhibitors used to test factor Xa as an antithrombotic target; the oral factor Xa inhibitors rivaroxaban, apixaban and edoxaban, used by millions of patients today, are synthetic molecules developed separately.

Rydel et al. (Genentech)

X-ray crystallography of hirudin bound to thrombin at 1.9 Å resolution revealed the bivalent binding mode (N-terminal active-site occupation + C-terminal exosite I binding) that explains hirudin's extraordinary K_d ≈ 20 fM affinity. Enabled rational design of bivalirudin (1990–1993) and subsequent next-generation DTIs.

Maraganore et al. (Biogen)

Bivalirudin — a 20-amino-acid semisynthetic peptide modeled on hirudin's thrombin-binding motifs — entered first-in-human trials for unstable angina. The Hirulog name reflected hirudin-analog design; bivalirudin would become the most successful leech-derived pharmaceutical.

Bayer (Behringwerke, Germany) — applicant

First recombinant hirudin approved by FDA for heparin-induced thrombocytopenia (HIT) with associated thromboembolism. Established direct thrombin inhibitor (DTI) as a clinical drug class. Voluntarily withdrawn 2012 due to declining demand after newer DTIs and DOACs supplanted use. Foundational landmark even after withdrawal.

The Medicines Company — applicant

FDA approval of bivalirudin for percutaneous coronary intervention (PCI). REPLACE-2, ACUITY, and HORIZONS-AMI trials established cardiovascular benefit. ACC/AHA Class I recommendation in selected PCI populations. Peak revenue $636M; over 1 million PCI procedures annually use bivalirudin worldwide.

Aventis (now Sanofi) — applicant

FDA approval of desirudin (Iprivask), a recombinant hirudin, for deep vein thrombosis prophylaxis after hip replacement — a subcutaneous DTI for orthopedic thromboprophylaxis. Desirudin is no longer marketed in the U.S.; its FDA listing is discontinued.

Ricarimpex SAS (Eysines, France) — applicant

FDA cleared medicinal leeches (Hirudo medicinalis) as a Class-cleared medical device for venous congestion in flaps/grafts/replants. The second living organism ever FDA-cleared as a medical device (after maggots K033391 in January 2004). Established the regulatory pathway for all subsequent medicinal leech 510(k) clearances. Product code NRN, Unclassified Pre-Amendment device.

Boehringer Ingelheim — applicant

FDA approval of dabigatran etexilate — the first oral direct thrombin inhibitor. The RE-LY trial showed the 150 mg dose superior to warfarin for stroke prevention in atrial fibrillation. Dabigatran is not derived from hirudin: Boehringer Ingelheim designed it from the thrombin-bound X-ray structure of NAPAP, a synthetic inhibitor made in Erfurt by the group of Fritz Markwardt, who had isolated hirudin in 1957. With the factor Xa inhibitors rivaroxaban, apixaban and edoxaban — synthetic molecules found by screening and structure-based chemistry — the DOAC era began.

Andreas Michalsen et al. (Charité Berlin)

First well-powered RCT (n=51) demonstrating significant pain reduction with leech therapy vs. topical diclofenac for knee osteoarthritis. Published in Ann Intern Med. WOMAC pain reduction 64% (leech) vs. 18.5% (diclofenac) at day 7; sustained at day 91 (p=0.002). NNT = 2.0 for clinically meaningful pain reduction. Foundational RCT for the off-label OA evidence base.

Stefan Andereya et al.

Multicentre prospective RCT (n=113) comparing leech therapy with hyaluronic acid injections for knee OA. Published in Forschende Komplementärmedizin. Confirmed substantial pain reduction with leech therapy; 2-year follow-up demonstrated durable benefit. Extended the Michalsen 2003 finding to a larger multicenter setting.

Marc Bäcker et al. (Charité Berlin)

An RCT of leech therapy for lateral epicondylitis (tennis elbow) — Bäcker et al., Clinical Journal of Pain (2011), n=40 — found significantly greater short-term pain relief with a single leech application than with topical diclofenac (pain sum score reduced ~34% at day 7). Established musculoskeletal evidence beyond OA, validating multi-target SGS mechanism in tendinopathy.

Iain S. Whitaker et al. (Swansea University)

Systematic review of 277 reported cases of leech-assisted microvascular flap salvage. Documented 88.3% salvage rate without infection vs. 37.4% with Aeromonas infection — a 51-percentage-point gap establishing infection prevention as the primary modifiable factor in treatment outcomes. The canonical reference for FDA-cleared indication evidence.

Kosta Y. Mumcuoglu (Hebrew University–Hadassah Medical School)

Published in Israel Medical Association Journal: definitive recommendation for fluoroquinolone (ciprofloxacin 500 mg BID) or TMP-SMX DS BID prophylaxis for all patients receiving leech therapy. Established the canonical prophylaxis protocol — beginning before first leech application, continuing through therapy + 24 hours after last application, extended to 10–14 days for immunocompromised patients.

Christian Herlin et al.

JPRAS systematic review establishing dual-agent prophylaxis (ciprofloxacin + TMP-SMX) as superior to monotherapy given case reports of ciprofloxacin-resistant Aeromonas infection after leech therapy. Refined the Mumcuoglu standard into the current dual-agent canonical protocol.

Liu et al. (Asian Pacific Symposium)

Integrated proteomics-transcriptomics catalog of medicinal leech salivary gland secretion identified hundreds of salivary proteins — a transformational expansion from the classical 30–40 characterized compounds. Established the modern foundation for systematic computational bioprospecting of the leech secretome. Babenko et al. 2020.

Kvist et al.; Babenko et al.

A draft genome assembly of Hirudo medicinalis, with proteome work attributed to Babenko et al. 2020, identified 15 anticoagulation factor genes + 17 additional antihemostatic protein genes. Established the genomic foundation enabling targeted recombinant expression and synthetic biology approaches.

Bobrovsky et al.

Pilot in vitro study: recombinant destabilase, the leech salivary isopeptidase that breaks ε-(γ-Glu)-Lys isopeptide bonds in stabilized fibrin, did not affect the intrinsic or extrinsic coagulation cascade and broke isopeptide bonds in natural human blood clots. The authors propose it as a potential drug for aged clots, which resist current thrombolytics (Curr Issues Mol Biol 2021, PMID 34889897).

Kosikowska et al. (Frontiers in Cellular and Infection Microbiology, 2022)

In a recreational freshwater reservoir all 69 Aeromonas isolates tested susceptible to ciprofloxacin or levofloxacin, yet 42% carried plasmid-mediated fluoroquinolone resistance (PMQR) genes, a hidden reservoir of resistance.

FDA

Medicinal leech 510(k) clearances transferred from the Center for Devices and Radiological Health (CDRH) to the Center for Biologics Evaluation and Research (CBER). New CBER tracking: K040187 → BK251211, K132958 → BK251217, K140907 → BK251218. Reflects regulatory recognition that medicinal leeches are biologically active products under the biologics framework.

J. Enzyme Inhibition and Medicinal Chemistry (2025)

Computational design of engineered hirudin variants in preclinical development. First demonstration that AI-driven structural design can produce next-generation DTIs. Validates the computational bioprospecting paradigm.

Kumar et al. (2025)

First systematic characterization of hirunipins — leech-derived antimicrobial peptides — as potential drug leads for the antimicrobial resistance crisis. Established the antimicrobial pipeline of leech salivary secretome as a candidate addressing WHO's #1 global health threat (AMR, projected 10M annual deaths by 2050).

ASH (501(c)(3) California nonprofit)

Establishment of the American Society of Hirudotherapy as the first U.S.-based independent professional society for evidence-based hirudotherapy. Operates an evidence library with an original analysis of each indexed publication, a trusted-sources network (71 authoritative references), and 12 frontier-research horizons spanning AI drug discovery to global health access. Mission: evidence over anecdote, transparency, regulatory clarity.